Haustein K O, Schenker E
Int J Clin Pharmacol Ther Toxicol. 1985 Apr;23(4):190-6.
In 16 healthy volunteers and in 39 patients with liver diseases (fatty liver, chronic persistent and chronic active hepatitis, hepatic cirrhosis) a simplified aminopyrine breath test (ABT) was carried out using a "tracer" dose of 3 mg (111 kBq) 14C-aminopyrine. The exhaled 14CO2 measured 1 h after intake amounted to values between 771 and 1337 DPM/mmol CO2/70 kg body weight in healthy controls. The amount of exhaled 14CO2 decreased in the order: fatty liver greater than chronic, active hepatitis greater than active, compensated cirrhosis greater than active, decompensated cirrhosis. Between the values of ABT and various conventional laboratory liver tests (alanine-aminotransferase, alanine-aminopeptidase, aspartate-aminotransferase, gamma-glutamyltransferase, total serum bilirubin) significant correlations were found (r = 0.6019 to 0.7765, n = 55; p less than 0.001). The proposed modification of the breath test is of advantage in that it requires a very low dose of aminopyrine and is easily practicable.
对16名健康志愿者和39名肝病患者(脂肪肝、慢性持续性肝炎、慢性活动性肝炎、肝硬化)进行了简化氨苯吡酮呼气试验(ABT),使用3毫克(111千贝可)14C - 氨苯吡酮的“示踪剂”剂量。健康对照组摄入后1小时测得的呼出14CO2量在771至1337每分钟衰变数/毫摩尔CO2/70千克体重之间。呼出14CO2量按以下顺序降低:脂肪肝>慢性活动性肝炎>活动性代偿期肝硬化>活动性失代偿期肝硬化。在ABT值与各种传统实验室肝脏检查(丙氨酸转氨酶、丙氨酸氨基肽酶、天冬氨酸转氨酶、γ-谷氨酰转移酶、总血清胆红素)之间发现了显著相关性(r = 0.6019至0.7765,n = 55;p<0.001)。所提议的呼气试验改进方法的优点在于它所需的氨苯吡酮剂量非常低且易于实施。